Skip to main content

Apimeds Pharmaceuticals US, Inc.

corporate_fare Company Profile

Apimeds Pharmaceuticals US, Inc.

APUS·NYSE·Life Sciences·CIK 0001894525

Apimeds Pharmaceuticals US, Inc. (ticker: APUS) is a clinical-stage biopharmaceutical company headquartered in Matawan, New Jersey, and was founded on May 11, 2020. The company is primarily focused on developing innovative therapies for inflammation and pain management. Its lead product candidate is Apitox, an intradermally administered bee venom-based toxin. Apitox is being developed as a potential treatment for knee osteoarthritis (OA), particularly for patients who have not responded adequately to conservative non-pharmacologic therapy and simple analgesics. A related formulation of Apitoxin has been used in South Korea for the reduction of pain associated with OA since 2003. Apimeds Pharmaceuticals US, Inc. is pursuing a second Phase III trial to meet FDA standards for Apitox in knee OA, with the intention to submit a Biologics License Application upon successful completion. The company also has an exploratory interest in multiple sclerosis (MS). Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Apimeds Inc., a South Korea-based entity, which is affiliated with Inscobee Inc. The company is a pre-revenue company, with its value dependent on successful clinical trials and regulatory approval. Apimeds Pharmaceuticals US, Inc. also has a digital asset operations segment, which includes the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave. This segment provides digital asset treasury solutions in bitcoin treasury infrastructure. Sources: [1] https://stocktwits.com/symbol/APUS/about [2] https://www.moomoo.com/stock/APUS-US/company?chain_id=Name1K9-3FXPhg.1lei900&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhans%2Fstock%2F9571-BMS%2Fcompany%22%7D [3] https://www.tradingview.com/symbols/AMEX-APUS/financials-overview/ [4] https://ir.apimedsus.com/company-info [5] https://tickeron.com/blogs/apimeds-pharmaceuticals-us-apus-tracking-a-bee-venom-candidate-for-osteoarthritis-35982/ [6] https://investbamboo.com/stocks/us/apus [7] https://stockanalysis.com/stocks/apus/company/

Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for APUS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Recent SEC coverage for APUS spans DEF 14A.

Recent high-impact activity:

  • Apimeds Proxy Sets Dec 23 Vote; Board Overhaul and Change of Control Loom

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$6M
Diluted EPS
-$0.55
Op. Cash Flow
-$8.93M
Free Cash Flow
-$8.98M
Operating Income
-$11.91M
Cash & Equivalents
$1.64M
Debt / Equity
0.00×
Shares Outstanding
12.58M sh
Source: 10-K · filed 2026-05-04 · accession 0001213900-26-051139

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 31,812 shares in APUS as of the October 30, 2026 settlement, a 56.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 45.6% of APUS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)31,812 shares as of October 30, 2026
Change vs prior period▼ 56.4%
Days to cover1.00 at avg daily volume of 66,825
Daily short volume (FINRA facilities)45.6% of 27,669 shares on November 20, 2026
5-day average short volume38.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$1.45 -9.38% today
52-week range · as of 2026-11-18 $1.45 – $59.7
Market cap
$2.96M
Volume
48.7K (0.4× avg)
3-mo avg 124.6K
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed APUS - Latest Insights

APUS
Nov 18, 2026, 5:15 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $1.73
Real-time Price: $1.45 info
Change: -$0.280 (-16%) info
Market Cap: $2.956M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets